📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Platinum Industries Q3 Revenue Jumps 31% YoY; Targets 35% CAGR Through FY29
Platinum Industries reported a strong Q3 FY26 with standalone revenue growing 31% YoY to ₹102.62 crores, driven by robust demand in the PVC pipe and fittings segment. The company has provided aggressive guidance, targeting over 40% revenue growth in FY27 and a 35% CAGR through FY29, supported by the upcoming Egypt facility and Palghar expansion. While gross margins moderated to 31% due to a higher mix of CPVC sales, the company remains net debt-free with a PAT of ₹12.93 crores for the quarter. Furthermore, the company is diversifying into the pharma sector through its new subsidiary, Rivadu LifeSciences, expecting revenue contributions starting in FY27.
Key Highlights
Standalone Q3 revenue rose 31% YoY to ₹102.62 Cr, while PAT increased 18% YoY to ₹12.93 Cr.
Management guided for a 35% revenue CAGR from FY26 to FY29, fueled by international expansion and new product lines.
Egypt facility construction is expected to finish by May 2026, with commercial production targeted for September 2026.
Palghar CPVC capacity is currently at 60-65% utilization, with lead-free stabilizer lines scaling up from April 2026.
Entered the pharma sector via 70% stake in Rivadu LifeSciences, focusing on niche APIs and nutraceuticals.
💼 Action for Investors
Investors should focus on the successful commissioning of the Egypt plant and the margin trajectory as the company scales its CPVC and pharma businesses. The strong growth guidance and debt-free status make this a compelling growth play in the specialty chemicals space.
Platinum Industries: Q3 Results with Modified Auditor Opinion; New Pharma Subsidiary Approved
Platinum Industries approved its Q3 and 9M FY26 results on February 12, 2026, which notably included a modified opinion from statutory auditors PKF Sridhar and Santhanam LLP. The company is diversifying into the pharmaceutical and lifesciences sector by incorporating a new subsidiary, Rivadu Lifesciences Private Limited. Platinum Industries will hold a minimum 70% stake in this new venture with an initial capital investment of up to Rs. 25 lakh. This move marks a strategic expansion into APIs, intermediates, and specialty chemicals.
Key Highlights
Board approved unaudited financial results for Q3 and 9M ended December 31, 2025, with a modified auditor opinion.
Incorporation of new subsidiary 'Rivadu Lifesciences Private Limited' approved for entry into the pharma sector.
Initial capital for the new subsidiary is set at up to Rs. 25,00,000 with Platinum Industries holding at least 70% stake.
The new business line will focus on APIs, pharmaceutical intermediates, excipients, and specialty chemicals.
Statutory auditors PKF Sridhar and Santhanam LLP issued the modified opinion on the financial results.
💼 Action for Investors
Investors should carefully examine the specific details of the auditor's modified opinion to identify potential financial or governance risks. The expansion into the pharmaceutical sector should be monitored closely as it represents a significant diversification from the company's core business.
Platinum Industries Enters Pharma Sector; Q3 Results Filed with Modified Auditor Opinion
Platinum Industries has announced a strategic diversification into the pharmaceutical and lifesciences sector through the incorporation of a new subsidiary, Rivadu Lifesciences Private Limited. The company will hold at least a 70% stake in the new venture, which has an initial capital outlay of Rs. 25 lakh. While the board approved the Q3 FY26 financial results, the statutory auditors have submitted their report with a modified opinion, which warrants investor attention. The new business line will focus on APIs, intermediates, and specialty chemicals.
Key Highlights
Board approved Q3 FY26 financial results for the period ended December 31, 2025.
Statutory auditors PKF Sridhar and Santhanam LLP issued a report with a modified opinion.
Incorporation of new subsidiary 'Rivadu Lifesciences' for entry into the Pharma/Lifesciences industry.
Initial capital for the new subsidiary is set at up to Rs. 25,00,000.
Platinum Industries will maintain a minimum 70% controlling stake in the new entity.
💼 Action for Investors
Investors should investigate the specific reasons behind the auditor's 'modified opinion' on the financial results as this can indicate accounting concerns. While the diversification into pharma is a growth signal, the execution and capital requirements for this new segment should be monitored closely.
Platinum Industries' Stake in Subsidiary Diluted to 89.49% Following Private Placement
Platinum Industries Limited has announced a change in the shareholding pattern of its subsidiary, Platinum Oleo Chemicals Private Limited. The subsidiary allotted 17,598 equity shares to new shareholders via a private placement on February 3, 2026. Consequently, Platinum Industries' stake in the subsidiary has decreased from 99.99% to 89.49%. The parent company did not participate in this allotment, resulting in a 10.5% dilution of its ownership.
Key Highlights
Subsidiary Platinum Oleo Chemicals Private Limited issued 17,598 equity shares of Rs. 10 each.
Parent company Platinum Industries' stake reduced from 99.99% to 89.49%.
The allotment was made to new shareholders through a private placement process.
The total nominal value of the allotment is Rs. 1,75,980, though the actual capital raised may differ based on the premium.
The move follows a board meeting outcome previously dated November 13, 2025.
💼 Action for Investors
Investors should monitor the strategic intent behind bringing new shareholders into the subsidiary and whether this precedes a larger expansion or capital expenditure plan.